TY  - ADVS
AU  - Hirsch,Fred R.
TI  - EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients
T2  - Cancer therapy : latest thinking in efficacy and toxicity,
PY  - 2009///
CY  - London
PB  - Henry Stewart Talks
KW  - Biomarkers
KW  - Neoplasms
KW  - complications
KW  - therapy
KW  - Receptor, Epidermal Growth Factor
KW  - antagonists & inhibitors
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules; Access restricted to subscribers
UR  - https://hstalks.com/bs/1123/
UR  - https://hstalks.com/bs/p/385/
ER  -